High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectrometry.

Although liquid chromatography/mass spectrometry using selected reaction monitoring (LC/SRM-MS) holds great promise for targeted protein analysis, quantification of therapeutic monoclonal antibody (mAb) in tissues represents a daunting challenge due to the extremely low tissue levels, complexity of tissue matrixes, and the absence of an efficient strategy to develop an optimal LC/SRM-MS method. Here we describe a high-throughput, streamlined strategy for the development of sensitive, selective, and reliable quantitative methods of mAb in tissue matrixes. A sensitive nano-LC/nanospray-MS method was employed to achieve a low lower limit of quantification (LOQ). For selection of signature peptides (SP), the SP candidates were identified by a high-resolution Orbitrap and then optimal SRM conditions for each candidate were obtained using a high-throughput, on-the-fly orthogonal array optimization (OAO) strategy, which is capable of optimizing a large set of SP candidates within a single nano-LC/SRM-MS run. Using the optimized conditions, the candidates were experimentally evaluated for both sensitivity and stability in the target matrixes, and SP selection was based on the results of the evaluation. Two unique SP, respectively from the light and heavy chain, were chosen for quantification of each mAb. The use of two SP improves the quantitative reliability by gauging possible degradation/modification of the mAb. Standard mAb proteins with verified purities were utilized for calibration curves, to prevent the quantitative biases that may otherwise occur when synthesized peptides were used as calibrators. We showed a proof of concept by rapidly developing sensitive nano-LC/SRM-MS methods for quantifying two mAb (8c2 and cT84.66) in multiple preclinical tissues. High sensitivity was achieved for both mAb with LOQ ranged from 0.156 to 0.312 μg/g across different tissues, and the overall procedure showed a wide dynamic range (≥500-fold) and good accuracy [relative error (RE) < 18.8%] and precision [interbatch relative standard deviation (RSD) < 18.1%, intrabatch RSD < 17.2%]. The quantitative method was applied to a comprehensive investigation of the steady-state tissue distribution of 8c2 in wild-type mice versus those deficient in FcRn α-chain, FcγIIb, and FcγRI/FcγRIII, following a chronic dosing regimen. This work represents the first extensive quantification of mAb in tissues by an LC/MS-based method.

[1]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[2]  N. Sadagopan,et al.  A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry. , 2009, Analytical chemistry.

[3]  Jos H Beijnen,et al.  Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. , 2009, Human antibodies.

[4]  B. Güttler,et al.  Protein quantification by isotope dilution mass spectrometry of proteolytic fragments: cleavage rate and accuracy. , 2008, Analytical chemistry.

[5]  I. Correia,et al.  Stability of IgG isotypes in serum , 2010, mAbs.

[6]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Jun Qu,et al.  Improved sensitivity for quantification of proteins using triply charged cleavable isotope-coded affinity tag peptides. , 2005, Rapid communications in mass spectrometry : RCM.

[8]  D. Hambly,et al.  Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies. , 2009, Analytical chemistry.

[9]  M. Ramanathan,et al.  Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. , 2010, Analytical chemistry.

[10]  B. Domon,et al.  Selected reaction monitoring applied to proteomics. , 2011, Journal of mass spectrometry : JMS.

[11]  D. Muddiman,et al.  Interplay of permanent charge and hydrophobicity in the electrospray ionization of glycans. , 2010, Analytical chemistry.

[12]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[13]  Joseph P. Balthasar,et al.  Investigation of the Influence of FcRn on the Distribution of IgG to the Brain , 2009, The AAPS Journal.

[14]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[15]  E. Ezan,et al.  Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. , 2008, Analytical chemistry.

[16]  J. Reichert Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[17]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[18]  J. Canty,et al.  Combinatorial peptide ligand library treatment followed by a dual-enzyme, dual-activation approach on a nanoflow liquid chromatography/orbitrap/electron transfer dissociation system for comprehensive analysis of swine plasma proteome. , 2011, Analytical chemistry.

[19]  J. Canty,et al.  A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. , 2009, Journal of proteome research.

[20]  Susan E Abbatiello,et al.  Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. , 2010, Analytical chemistry.

[21]  Andrew N Hoofnagle,et al.  The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. , 2009, Journal of immunological methods.

[22]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[23]  Darrell Ricke,et al.  Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. , 2008, Analytical chemistry.

[24]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[25]  Hao Wang,et al.  Accurate localization and relative quantification of arginine methylation using nanoflow liquid chromatography coupled to electron transfer dissociation and drbitrap mass spectrometry , 2009, Journal of the American Society for Mass Spectrometry.

[26]  Alain Balland,et al.  Characterization of nonenzymatic glycation on a monoclonal antibody. , 2007, Analytical chemistry.

[27]  J. Mesirov,et al.  Prediction of high-responding peptides for targeted protein assays by mass spectrometry , 2009, Nature Biotechnology.

[28]  Olivier Heudi,et al.  Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.

[29]  R. Straubinger,et al.  Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. , 2007, Analytical chemistry.

[30]  Kinetics of chemical degradation in monoclonal antibodies: relationship between rates at the molecular and peptide levels. , 2010, Analytical chemistry.

[31]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[32]  Daniel B. Martin,et al.  Computational prediction of proteotypic peptides for quantitative proteomics , 2007, Nature Biotechnology.

[33]  Jin Cao,et al.  A rapid, reproducible, on-the-fly orthogonal array optimization method for targeted protein quantification by LC/MS and its application for accurate and sensitive quantification of carbonyl reductases in human liver. , 2010, Analytical chemistry.

[34]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[35]  Ruedi Aebersold,et al.  Mass spectrometry based targeted protein quantification: methods and applications. , 2009, Journal of proteome research.

[36]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[37]  Mathieu Dubois,et al.  Bioanalysis of recombinant proteins and antibodies by mass spectrometry. , 2009, The Analyst.

[38]  P. Carter Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.